Table 5. Summary of the analyzed studies and the distribution of methylenetetrahydrofolate reductase ATIC 347C > G (rs2372536) genotypes.
| Study | Study design | Genotype counts |
Mean age, years | Mean disease duration, years | MTX dose (mg per week) (range or mean ± s.d.) | Date of end point (week) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Responders |
Nonresponders |
||||||||||
| (Case) |
(Control) |
||||||||||
| CC | CG | GG | CC | CG | GG | ||||||
| Ghodke-Puranik Y et al.15 | Retrospective cohort | 11 | 25 | 13 | 38 | 83 | 42 | 43.8 ± 10.4 | 5.6 ± 4.9 | 15.0 ± 3.9 | 48 |
| Takatori R et al.35 | Prospective cohort | 48 | 21 | 3 | 19 | 11 | 3 | 59.2 | 4.04 | 6 | >20 |
| Salazar J et al.23 | Prospective cohort | 26 | 15 | 4 | 5 | 9 | 2 | 55.62 ± 1.297 | 5.55 | 7.5–25 | >24 |
| Wessels JA et al.20 | Prospective cohort | 51 | 30 | 6 | 46 | 62 | 10 | 54.6 ± 13.3 | <2 years | 15 or 25 | >18 |
| Sharma S et al.22 | Prospective cohort | 61 | 97 | 47 | 16 | 41 | 11 | GR* 45.0 ± 11.50, PR 40.9 ± 12.7 | <5 years | Up to 25 | >24 |
*GR: Good response; PR: Poor response.